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Abstract 
The proteins involved in the autophagy (Atg) pathway have recently been considered promising 
targets for the development of new antimalarial drugs. In particular, inhibitors of the protein-protein 
interaction between Atg3 and Atg8 of P. falciparum retarded the blood- and liver-stages of parasite 
growth. In this paper, we used computational techniques to design a new class of peptidomimetics 
mimicking the Atg3 interaction motif, which were then synthesized by click-chemistry. Surface 
Plasmon Resonance (SPR) has been employed to measure the ability of these compounds to inhibit 
the Atg3-Atg8 reciprocal protein-protein interaction (PPI). Moreover, P. falciparum growth 
inhibition in red blood cell cultures was evaluated as well as the cyto-toxicity of the compounds. 
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INTRODUCTION 
Malaria is one of the deadliest parasitic diseases with an estimated 212 million clinical cases in 
2015, causing 429.000 deaths [1]. More than two thirds (70%) of these deaths are children under 5 
years old, who are particularly susceptible to infection and illness. Malaria is thus a major killer of 
children in this age group, taking the life of a child every two minutes [1]. 
Malaria burden is caused by the Plasmodium parasites, transmitted through the bite of the 
infected female anopheline mosquitoes. The species able to infect humans are P. falciparum, P. 
vivax, P. malariae, and P. ovale, the first being the most lethal one. Together with P. vivax, P. 
falciparum accounts for more than 95% of malaria cases in the world [2]. Moreover, in South East 
Asia, monkey-to-human transmission of P. knowlesi infections have also been reported [3]. 
Several treatments of malaria are available, but it has become evident that all classes of drugs 
provoke parasite resistance, such as that recently reported for artemisinins [4,5], limiting the 
efficacy of the applied therapy. After intense research efforts by big pharmaceutical companies and 
nonprofit organizations, the new malaria vaccine RTS,S/AS01, developed by GlaxoSmithKline 
Biologicals and the “PATH Malaria Vaccine Initiative”, will be rolled out in pilot projects in three 
countries in sub-Saharan Africa [6]. However, current available data from these studies suggest 
limited protection through the vaccine of about 30-40% [7]. It follows that new targets for the 
design and development of antimalarial drugs are urgently needed [8].  
A promising strategy to develop new drugs is to target the proteases of malaria parasites, which 
are involved in the processes of host erythrocyte rupture, erythrocyte invasion and hemoglobin 
degradation. In particular, attention has been focused on falcipain-2, for which some potent 
inhibitors have been reported [9,10]. More recently, new experimental evidence suggested the 
importance of autophagy in differentiation, development and survival of pathogenic parasites 
[11,12] such as P. falciparum [13] or Toxoplasma gondii [14,15]. Autophagy is an intracellular 
degradation process in which the cellular contents are enveloped by phospholipid bilayers 
(autophagosome) and then fused with lysosomes or vacuoles. In mammals, over thirty different 
subtypes of autophagy-related proteins (Atg) are involved in this process. Among them, Atg8 seems 
to be essential for the formation of autophagosomal membranes. The association of Atg8 to the 
membrane results from its coupling with phosphatidylethanolamine (PE). This event, triggered by a 
post-translational modification process known as “lipidation,” is accomplished by the Atg8 
conjugation system. This process involves Atg proteins such as Atg4 (member of the caspase 
family), Atg7, Atg3 and the Atg5-Atg12 complex.  The first of these (Atg4), undergoes cleavage of 
the C-terminal residues, which activates Atg8 and promotes the binding of a cysteine residue of 
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Atg7 to the Atg8-G116. This forms a thioester bond in an ATP-dependent manner. Then, the 
activated form of Atg8 is available for association with Atg3 by a thioester bond. Ultimately, the 
Atg5-Atg12 complex assists [16] the Atg8-Atg3 dissociation and the coupling of the Atg8’ N-term 
to a PE molecule composing the membrane via an amide bond. Atg8-PE then prompts the assembly 
of source membranes into the membranes of autophagosomes [17]. 
In parasites such as P. falciparum [13] and T. gondii [15] autophagy is carried out by a simplified 
cellular processes, yet it is known that Atg8 was found to be essential to the parasite survival and it 
is expressed during all stages of their growth [18,19]. Consequently, the Atg8-Atg3 protein-protein 
interactions (PPIs) have been deemed a promising target for the development of new drugs active in 
blood and liver stages of the parasite infection [20,21].  
The X-ray crystal structure of the P. falciparum (Pf) Atg3-Atg8 complex (PDB ID: 4EOY [13]) 
paved the way to the computer-aided design of new potential drug candidates, revealing that PfAtg8 
provides multiple sites (W and L) that anchor PfAtg3 (Fig. 1). An additional region of the protein, 
the A-loop, has high sequence diversity among different parasites and humans. This has been the 
object of Hain et al. [20] studies leading to the identification of ALC25 (Fig. 1), which significantly 
inhibits the PfAtg3-PfAtg8 PPI, in contrast to the 4-pyridin-2-yl-1,3-thiazol-2-amine (PTA) class of 
compounds [21], which binds to the W- and L- sites.  
 
Fig. 1 X-ray structure of PfAtg8 (gray surface) in complex with PfAtg3 (green stick model, PDB ID: 4EOY). 
Chemical structures of ALC25 and of a representative PTA containing derivative, known as Atg8-Atg3 PPI inhibitors. 
PTA moiety is colored in blue. 
 
In this paper, taking into account the structural insights from the PfAtg3-PfAtg8 X-ray complex, 
we report the computational design and the synthesis of new potential PfAtg3-PfAtg8 PPI 
inhibitors, and their subsequent testing by Surface Plasmon Resonance (SPR) and P. falciparum 
growth inhibition assays. 
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RESULTS AND DISCUSSION 
Design of PPI inhibitors. PPI inhibitors are compounds capable of impairing the molecular 
interactions between protein partners [22]. Peptidomimetics belong to a class of PPI inhibitors that 
retain the molecular features of the peptide to be mimicked, in which peptide bonds are replaced by 
more enzymatically stable bonds. Therefore, the ideal PfAtg3’ peptidomimetic is a compound able 
to reproduce the contacts formed by the template structure (sequence NDWLLPSY), while one or 
more peptide bonds are replaced by new moieties. Due to the variety of interactions shaped by the 
amino acids of PfAtg3 in the X-ray complex, the hot spots responsible for the PPI should be 
identified in order to design ligands that mimic the essential contacts only. To this aim, we 
identified the minimal active sequence of PfAtg3 by performing molecular dynamics (MD) 
simulations on the solvated PfAtg3/PfAtg8 X-ray complex. This analysis revealed that PfAtg3 
interacts with PfAtg8 by: i) the H-bond between the side chains of PfAtg3-N103 and PfAtg8-E17, 
ii) the projection of the PfAtg3-W105 indole ring into the W-site of PfAtg8 shaped by residues E17, 
T18, I21, P30, K58 and Y113, iii) the H-bonds of PfAtg3-L106 with the backbone atoms of 
PfAtg8-L50 and PfAtg8-K58, iv) the H-bond between PfAtg3-Y110 and PfAtg8-Met55, v) the van 
der Waals (vdW) contacts between the side chain of PfAtg3-L106 and those of PfAtg8-F49 and 
PfAtg8-H67, and finally vi) the vdW contacts of the PfAtg3-P108’ pyrrolidine ring with the 
PfAtg8’ pocket sized by residues F49, V51, F60 and M55 (L-site). MD simulations on this complex 
also showed that the main contributors to the PfAtg8-PfAtg3 PPI were located in the middle of the 
PfAtg3 sequence (core region, Fig. 2A), i.e., the amino acids WLLP. In fact, after over 100 ns of 
MD simulations, the root mean square fluctuation (RMSF) of the Cα atoms belonging to PfAtg3’ 
core region was lower than 1.1 Å, at variance with the residues at the PfAtg3’ C- and N- terms 
showing higher values (Fig. 2B). This was the consequence of the stability showed by the 
interactions (H-bonds and vdW contacts) engaged by PfAtg3-WLLP, further reinforced by the 
creation of two additional H-bonds between the backbone atoms of PfAtg3-D104 and those of 
PfAtg8-K47 and PfAtg8-K48.  
Conversely, the high conformational mobility showed by residues belonging to the PfAtg3’ 
terminal residues was caused by the loss of the H-bond between the side chains of PfAtg3-N103 
and PfAtg8-E17. Moreover, an H-bond between PfAtg3-Y110 and PfAtg8-E59 was only 
occasionally shaped, at the expense of the PfAtg3-Y110/PfAtg8-Met55 contact found in the 
crystallized complex. All distance fluctuations over MD simulations can be found in Fig. S1, 
Electronic supplementary material 1. 
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Fig. 2 A) WLLP segment of PfAtg3 (yellow stick model) in complex with PfAtg8 (colored as green stick model). 
Hydrogen bonds are represented as yellow dashed lines. B) Cα-RMSF of PfAtg3 within the PfAtg8 binding site over 
MD simulations. 
 
In concordance with the calculated predictions, the WLLP sequence of PfAtg3 was identified as 
the most suitable structure to be mimicked by new PfAtg3-PfAtg8 PPI inhibitors. The chemistry of 
peptidomimetics provides several molecular fragments capable of reproducing the peptide’s 
primary and secondary structures [23,24]. Among them, 1,2,3-triazoles are heterocycles with 
interesting properties for application in peptide sciences since they are amide bioisosteres and are 
resistant to enzymatic degradation. These properties make 1,2,3-triazoles promising candidates for 
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the development of novel PfAtg3 peptidomimetics with potentially improved biological profiles 
[23]. Furthermore, 1,4-disubstituted 1,2,3-triazoles have gained relevance in medicinal chemistry 
due to their synthetic accessibility by click 1,3-dipolar cycloaddition reaction between azides and 
alkynes under copper salts catalysis. Consequently, we designed new PfAtg3 analogues in which: i) 
a 1,4-disubstituted 1,2,3-triazole moiety replaced the PfAtg3’ L106-P107 amide bond, ii) a phenyl 
ring replaced the isopropyl chain of PfAtg3-L106, aiming to engender τ or π-π interactions with the 
PfAtg8-F49 phenyl ring (Fig. 2A), and iii) a tryptophan was preserved in the N-term (Fig. 3), to 
optimally fill the W-site.   
The substituent to be introduced in position 1 of the 1,2,3-triazole ring should occupy the PfAtg8’ 
L-site, and is expected to promote additional interactions with the PfAtg8-R28 side chain 
surrounding that site (see Fig. 2A). In our hypothesis, a pyridine or a pyridazine ring should create 
suitable H-bonds with the guanidine group of PfAtg8-R28; the optimal length of the spacer linking 
these heterocycles and the 1,2,3-triazole ring remained to be established. We therefore undertook 
the prediction of the size of the spacer by performing docking calculations on a small series of 
suitably designed peptidomimetics (Fig. 3).  
 
Fig. 3 General structure of the small set of designed compounds, in comparison with 
the template structure (PfAtg3-WLLP). 
 
   The results (Fig. S2, Electronic supplementary material 1) showed that the pyridine and 
pyridazine derivatives, linked by an ethylene spacer to the 1,2,3-triazole ring, displayed the highest 
theoretical score in binding the target protein. Noteworthy, they displayed docking score identical to 
the one acquired by WLLP, showing experimental KD value of 326 nM [13]. We supposed that: i) 
the pyridazine/pyridine ring could interact with the PfAtg8-R28 side chain by hydrogen bonds, ii) 
the triazole ring could create a hydrogen bond with the NH of PfAtg8-L50, iii) the N-term group 
(protonated) of the ligands interacted with the carbonyl group of PfAtg8-K48 by a hydrogen bond, 
and iv) the tryptophan moiety occupied the PfAtg8’ W-site (Fig. 4). The superimposition of the new 
peptidomimetics and the PfAtg3 X-ray pose showed a good overlapping between the template 
structure PfAtg3 and the newly designed ligand structures (Fig. 4A).  
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Fig. 4 A) Superimposition of pyridazine derivative (orange stick models) and PfAtg3 (yellow stick models) within 
the binding site of PfAtg8 (green stick models). Hydrogen bonds are represented as yellow dashed lines. B) 
Hypothetical binding mode of the pyridazine analogue in the PfAtg8 binding site. The protein surface is colored 
accordingly with the partial charge of the residues, red and blue for negative and positive charges, respectively. Surface 
and atom partial charges were acquired by Pymol software. 
 
MD simulations were also performed on the (S,S)-pyridazine analogue within PfAtg8 and, at the 
end of the simulations (100 ns), the obtained trajectories showed that the ligand was almost stable in 
the binding site. In fact, the phenyl ring of the ligand created vdW contacts with the side chain of 
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the PfAtg8-F49 (Fig. S3A, Electronic supplementary material 1). The triazole ring retained the H-
bond with the NH group of PfAtg8-L50 (Fig. S3B, Electronic supplementary material 1), and the 
indole ring was firmly inserted in the W-site (Fig. S3C, Electronic supplementary material 1). 
Similarly, the H-bond between the N-term of the ligand and the backbone of PfAtg8-K48 was 
maintained (Fig. S3D, Electronic supplementary material 1). On the other hand, the pyridazine ring 
of the ligand was not firmly inserted in the L-site, in fact the predicted H-bond of the pyridazine 
ring with PfAtg8-R28 during docking calculations was lost during the early stages of MD 
simulations (Fig. S3E, Electronic supplementary material 1). 
Taking these theoretical outcomes into consideration, we synthesized the designed 
peptidomimetics. The planned synthetic strategy led to two pairs of diastereoisomers (Fig. 5, 
compounds 1, 2 and 3, 4). Additional molecular modeling studies, supported by high-field NMR 
spectroscopy, were necessary to assign the absolute configurations to the stereocenters, after which 
the biological activity of the peptidomimetics was evaluated by SPR and P. falciparum growth 
inhibition tests. 
 
Fig. 5 Chemical structure of target compounds. 
 
Synthesis of compounds 1-4. Synthesis of compounds 1, 2 and 3, 4 (Fig. 5) were performed by 
click reactions from alkyne 7 (Scheme 1) and the azides 12 and 13 (Scheme 2) respectively. Alkyne 
7 was obtained from 1-phenyl-2-propyn-1-ol (Scheme 1) that, by treatment with acetonitrile, in 
presence of sulfuric acid and Na2SO4, was converted into the amide 5 [25]. The latter was 
hydrolyzed in acidic conditions and the resulting amine 6 was coupled with N-α-Boc-(L)-
tryptophan, in the presence of EDAC and HOBt, to give the key intermediate 7. 
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Scheme 1. Reagents and conditions: a. H2SO4, Na2SO4, CH3CN, N2,  r.t., 48 h; b. 3.5 M HCl, 90°C, 4 h; c. N-α-Boc-
(L)-tryptophan, HOBt·H2O, EDAC, CH2Cl2, N2, r.t., 16 h. 
 
Azide 12 was synthesized from the commercially available 2-(pyridin-2-yl)ethanol 8, meanwhile 
azide 13  was obtained from 3-methyl pyridazine that was converted in the corresponding 2-
(pyridazin-3-yl)ethanol 9 in the presence of formaldehyde (Scheme 2). The alcohols 8 and 9 were 
treated with methanesulfonyl chloride to afford the intermediates 10 and 11, which were then 
converted into the corresponding azides 12 and 13 by treatment with NaN3 [26]. 
Finally, the cycloaddition of alkyne 7 to azides 12 and 13, in the presence of CuSO4 and sodium 
(L)-ascorbate, provided the intermediates 14 and 15; removal of the tert-butoxycarbonyl group by 
treatment with trifluoroacetic acid, afforded the pairs of products 1, 2 and 3, 4 respectively. The 
diasteroisomers were quantitatively separated by flash chromatography (Scheme 3). 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: a. 37% CH2O, piperidine, H2O, N2, MW, 165°C, 30 min; b. MsCl, DIPEA, 
CH2Cl2, r.t., 3 h; c. NaN3, DMF, 70°C, 3 h. 
 
 
 
Scheme 3. Reagents and conditions: a. CuSO4, sodium (L)-ascorbate, tert-butanol, H2O, rt, 18 h; b. TFA, CH2Cl2, 
r.t., 3 h. 
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Configuration assignment of diastereoisomers 1, 2 and 3, 4. To assign the configuration of 
diastereoisomers 1,2 and 3,4 we decided to combine NMR spectroscopy and computational 
methods, as described in previous publications [27-29]. Here, the 1H NMR spectra of 1 vs 2 and 3 
vs 4 showed significantly different resonances of the triazole and the ortho phenyl protons (see 
Table 1), suggesting that the chemical environments of these protons is sufficiently different for the 
two diastereoisomers to deeply influence their chemical shifts. For this reason we decided to 
accomplish a complete assignment for compounds 1-4 1H resonances (Electronic Supplementary 
material 2) and compare the obtained data with the corresponding calculated chemical shifts based 
on previously optimized geometries.  
The 1H NMR chemical shifts of compounds 1-4 are shown in Table S1. Some NOE correlations 
(NOE1-4, Electronic supplementary material 2) were also related to the conformations of 1-4 and 
were used to drive the following modeling experiments. The conformational study was performed 
on the simplified structures (R,S)-16 and (S,S)-17 (Fig. 6) that correspond to the two epimers for 
compounds 1-4. All the degrees of conformational freedom were considered; in particular, the 
orientation around the single bonds exemplified by the curved arrows in Fig. 6. The various 
geometries were all optimized at the B3LYP/6-31G(d) level [30,31]. 
 
 
Fig. 6 Simplified structures corresponding to the epimers of compounds 1-4.  
 
For construction of the starting geometries, attention was initially focused on conformations 
showing the experimentally determined NOESY correlations (see above). Epimer 16 had a greater 
distribution of the population between the different conformations, while in the case of 17 only 
three geometries were significantly populated (Electronic supplementary material 2, Fig. S1 and 
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Table S2). We finally computed the 1H NMR chemical shifts for each populated conformation of 
compounds 16 and 17 (Table 1) using GIAO NMR calculations [32,33] at the same DFT B3LYP/6-
31G(d) [30,31] level already used for the optimizations. The close agreement between experimental 
and theoretical data of the triazole and the ortho phenyl protons (Table 1) allowed the 
configurational assignment: 1 and 3 were the diastereoisomer (R,S) while 2 and 4 were the 
diastereoisomer S,S. 
 
Table 1. B3LYP/6-31G(d) GIAO calculated 1H NMR chemical shift (δ, in 
ppm relative to TMS) of some key protons of compounds 16 and 17 based 
on the geometries optimized at the same level in comparison with the 
experimental values from the recorded spectra in compounds 1-4.  
 
Compound δ 
HαTRZ 
δ 
Ha,e-Bn 
δ 
HaTHR 
16 (R,S) 6.56 7.13 6.96 
17 (S,S) 7.65  6.92 6.86 
1 6.85 7.09 7.07 
2 7.35 6.83 6.97 
3 6.97 7.13 7.09 
4 7.52 6.85 7.00 
 
Biophysical and biological investigations on compounds 1-4. We tested compounds 1-4 for in 
vitro inhibition of the plasmodial Atg8-Atg3 PPI using our established SPR competition assay 
[13,21,20]. Recombinant proteins for the SPR assay were purified as previously described [13]. 
Each inhibitor was dissolved in the running buffer and tested in triplicates in a 12-point, two-fold 
dilution series ranging from 0.49 µM to 1000 µM(Fig. 7A). To assess the SPR chip’s integrity over 
the course of the experiment, the uninhibited (control) interaction of Atg8 with Atg3 in the presence 
of DMSO was run at regular intervals between the inhibition tests. The response of the control 
interaction was maintained throughout the experiment. Therefore, the chip surface was not 
compromised by any of the compounds, or the time it took to complete the dose-response 
experiment. At high concentrations (500µM – 1000µM), the compounds started precipitating in the 
SPR running buffer and those data were thus omitted for the IC50 calculation of each compound. A 
dose-dependent inhibition of the Atg8-Atg3 interaction was observed in all four compounds with 
increasing amounts of the inhibitory molecules, indicating that the described molecules are indeed 
able to specifically block the interaction of PfAtg3 with PfAtg8. The IC50 calculated from the 
normalized SPR response were 1 20 µM, 2 3.8 µM, 3 12.4 µM, 4 17.4 µM. No stereoselectivity of 
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the PPI inhibition was observed in the SPR assay between the (R,S) and the (S,S) diastereoisomers, 
however, we found stereoselectivity when we evaluated the growth inhibition of P. falciparum 
3D7-infected blood-stage cultures using the SYBR green assay, which measures binding of a 
fluorescent dye to parasite-derived DNA (Fig. 7B). That the growth inhibition assays demonstrate a 
clear preference for the (R,S) diastereoisomer while the SPR assay does not is consistent with a 
situation in which some up-stream transporter or process, present only in in culture context, is 
stereoselective even though the PPI inhibition itself is not. This may be observed in the result that, 
as measured by SPR, compound 2 had the most prominent inhibition with an IC50 of 3.8 µM, yet 
was found to be essentially inactive in the in culture SYBR green assay with an IC50 of about 560 
µM.  In culture, compound 1 had the most prominent, albeit still modest, inhibitory effect with an 
IC50 of about 40 µM. In support of stereoselectivity of the inhibitory effect in an in culture context, 
an approximately ten-fold increase in potency was observed both times the (R,S) diastereoisomer 
was used to prevent P. falciparum growth, implying the in culture processes are more efficient at 
transporting the (R,S) diastereoisomer into the cell and thereby providing compound 1 with access 
to the PfAtg3 and PfAtg8 interface. The counterintuitive result of 2 emphasizes the need for the 
cross-validation of assays using multiple readout methods, enabling the early differentiation of 
putative lead compounds.  
 
 
Fig. 7 A) SPR PPI inhibition study. The normalized SPR response for each compound is plotted versus the 
logarithmic inhibitory concentration in M.  All four compounds were tested in the range of 0.4 – 250 µM. B) SYBR 
green growth inhibition assay of P. falciparum 3D7 strain with calculated IC50 values. Compound 1 and 3 are the R,S 
diastereoisomers while 2 and 4 are the S,S diastereoisomers. 
 
 
Compounds 1 and 2 do not show any cytotoxic effect on HepG2 viability. MTT experiments 
were performed in order to exclude the potential toxic effects of compounds 1 and 2 on the HepG2 
cell line (Fig. 8). Compounds 1 and 2 were tested at concentrations ranging from 1 to 100 μM and 
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no significant cell mortality was observed at all tested doses after 24 and 48 h treatment versus 
vehicle (C, DMSO). These data suggest that both compounds do not induce any cell mortality in 
this dose range.  
 
Fig. 8 . Bar graphs indicating the results of MTT cell viability assay of HepG2 cells after compounds 1 and 2 
treatment for 24 and 48 h. The data points represent the averages ± SD of three independent experiments in triplicate. 
 
CONCLUSION 
      The crystal structure of the PfAtg3-PfAtg8 complex ushered in the possibility of computer-
aided drug design of new PfAtg3’ peptidomimetics with potential antimalarial activity. In this 
paper, the X-ray crystal structure of the PfAtg3-PfAtg8 complex was geometrically optimized by 
energy minimization and MD simulations. The analysis of the resulting trajectories supported the 
evidence that the WLLP sequence of PfAtg3 displayed the lowest conformational freedom in the 
PfAtg3-PfAtg8 complex; therefore WLLP was chosen as template for the design of new 
peptidomimetics incorporating a substituted 1,2,3-triazole ring, which is a known amide bioisostere. 
A small set of compounds was designed and screened by docking calculations, and two pairs of 
diastereoisomers (compounds 1-4) were then selected and synthesized through a click-chemistry 
approach. In each diastereomeric pair, NMR and conformational analysis studies allowed 
unequivocal assignment of the absolute configuration to the stereocentres. 
Biological assays showed that the PfAtg3-PfAtg8 association was inhibited in the SPR assay by 
both diastereoisomers. Noteworthy, the (R,S) diastereoisomers 1 and 3 were about tenfold more 
potent in inhibiting parasite growth than their corresponding (S,S) counterparts 2 and 4. This 
suggests that inhibitors with the (R,S) configuration of the peptidomimetic drug could be either 
more efficiently transported across the red blood cell membrane and/or the parasite plasma 
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membrane, or that inhibitors having the (S,S) configuration are degraded faster in a cellular context 
by peptidases.  
The most active isomers 1 and 3 showed a comparable IC50 value of about 40 µM in a 
Plasmodium falciparum growth inhibition assay. MTT experiments on compounds 1 and 2 showed 
that they do not induce any cell mortality. However, further efforts are needed to design more active 
compounds, capable to fully and stably occupy the L-site of the target protein PfAtg8. In fact, as 
suggested by MD simulations, the pyridazine moiety of the pyridazine derivatives (3-4) could not 
be firmly bound in the L-site of PfAtg8, and this could explain the low biological activity showed 
by these compounds.  
The results attained in this initial study point at the research of peptidomimetics in this area to 
novel inhibitors endowed with the (R,S) absolute configuration, with the pyridazine moiety that 
should conceivably be replaced by a molecular fragment more stably bound to the PfAtg8’ L-site. 
Computational and synthetic studies aiming to identify more efficient PfAtg3-PfAtg8 PPI inhibitors 
are still ongoing. 
 
EXPERIMENTAL PROTOCOL 
Molecular dynamics simulations. MD simulations of the PfAtg3-PfAtg8 and the PfAtg8/4 
complexes were performed by assigning the force field parameters of AMBER12 [34] package. 
Accordingly, the proteins were treated by the ff12SB force fields, and GAFF was employed for the 
treatment of ligand [35], and the TIP3P model [36] was used to represent the solvent molecules. A 
cubic box of water, with a minimum distance of 20 Å from the protein surface, was built. Prior to 
starting MD simulations, a minimization of the bulk water molecules was carried out, using a 
gradient criterion convergence of 0.2 kcal mol-1 Å-1. Then, the whole system was optimized by 
applying a convergence criterion of 0.0001 kcal mol-1 Å-1 and next equilibrated gradually 
increasing the temperature to 300 K, over 60 ps. Finally, a production run of 100 ns was performed. 
Van der Waals and short-range electrostatic interactions were taken into account within a 10 Å 
cutoff, while long-range electrostatic interactions were assessed using particle mesh Ewald method 
[37]. Berendsen's coupling algorithms [38] were active to maintain the temperature at 300 K and the 
pressure of the system at 1 atm, by a coupling constant set to 1.5 ps. Pmemd.cuda module of 
AMBER12 performed the production runs of MD simulations. 
 
Docking studies. Docking calculations of the (S,S) pyridazine analogue (Fig. 5) were performed 
by GOLD5.2.2 algorithm [39] using the crystal structure of PfAtg8 deposited in the Protein Data 
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Bank with the code 4EOY, chain B [13]. The binding site was defined by selecting the residues 
included in a sphere with a radius of 13.0 Å from the Cα atom of Phe49. Amino and carboxyl 
groups were considered in the ionized form for consistency with the expected protonation state at 
physiological pH. ChemPLP scoring function [40] was employed while the genetic algorithm 
parameters were kept at their default values, as already done in previous studies [41]. At the end of 
docking calculations, poses were clustered by the complete-linkage method [39]. This is an 
agglomerative hierarchical clustering algorithm in which, initially, each element is located in a 
different singleton cluster, then clusters are combined into larger clusters until all elements are in 
the same cluster.  At each step, the two clusters separated by the shortest distance are combined 
[39]. Finally, the clusters were ranked depending on the obtained score. The solution representative 
of each cluster was the one which obtained the highest docking score. 
 
Chemistry. Reagents and solvents were purchased from Sigma-Aldrich and used without further 
purification. Reactions were performed through conventional conditions or by a microwave 
synthesizer (Initiator 2.0 Biotage). The reactions involving air-sensitive reagents were carried out 
under nitrogen atmosphere and anhydrous solvents were used when necessary. Reactions were 
monitored by thin layer chromatography analysis on aluminum-backed Silica Gel 60 plates (70-230 
mesh, Merck), using an ultraviolet fluorescent lamp at 254 nm and 365 nm. Visualization was aided 
by opportune staining reagents. Purification of intermediates and final compounds was performed 
by flash chromatography using Geduran® Si 60 (40-63 µm, Merck).  
1H and 13C NMR spectra were recorded in CDCl3 and CD3OD on a Variant 300 MHz Oxford 
equipped with a non-reverse probe at 25° C. Chemical shifts are expressed as δ (ppm) and are 
referenced to residual solvent proton/carbon peak. Multiplicity is reported as s (singlet), br s (broad 
singlet), d (double), t (triplet), q (quartet), m (multiplet), dd (double of doublets), dt (doublet of 
triplets). The coupling constants (J-values) are given in Hertz (Hz). All spectroscopic data match the 
assigned structures. ESI-MS analyses were performed by using a LQT- Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific) with an electrospray ionization source (Finningan 
IonMax). Melting points were determined on a Buchi Melting Point B540 instrument. Optical 
rotations were determined by the polarimeter JASCO P-1010, at 25 °C.  
 
Procedure for the synthesis of tert-butyl ((2S)-3-(1H-indol-3-yl)-1-oxo-1-((1-phenylprop-2-yn-1-
yl)amino)propan-2-yl)carbamate (7). Synthesis of N-(1-phenylprop-2-yn-1-yl)acetamide (5) [25]. 
To a suspension of 1-phenyl-2-propyn-1-ol (500 mg, 3.783 mmol) and Na2SO4 (537 mg, 3.783 
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mmol) in CH3CN (6 mL) at -25°C under stirring, a solution of 97% H2SO4 (1 mL) in CH3CN (3.9 
mL) was added dropwise. The mixture was stirred at room temperature for 48 h. Afterwards the 
solvent was concentrated and ice was added to the suspension that was extracted by diethyl ether (3 
× 5 mL) and dichloromethane (3 × 5 mL). The organic layer was dried and evaporated under 
vacuum. The crude was purified by flash chromatography (eluent mixture: diethyl ether/petroleum 
ether 5:5) to give the white solid 5 (655 mg, 3.782 mmol). 
Yield: quantitative; M.p. 88.8-89.8 °C; 1H NMR (300 MHz, CDCl3) δ 1.62 (s, 1H), 2.02 (s, 3H), 
2.49 (d, J = 3 Hz, 1H), 6.02 (d, J = 3 Hz), 7.23-7.55 (m, 5H).  
 
Synthesis of 1-phenylprop-2-yn-1-amine (6) [42]. N-(1-phenylprop-2-yn-1-yl)acetamide (5)  (465 
mg, 2.684 mmol) was suspended in 3.5M HCl (15.5 mL) and heated to 90°C under stirring for 5 h. 
After cooling, the solution was extracted with diethyl ether (1 × 5 mL) and the aqueous layer was 
basified by adding solid NaHCO3 until pH 8.5 and subsequently extracted with diethyl ether (3 × 10 
mL). The organic layer was dried and concentrated in vacuo. The crude was purified by flash 
chromatography (eluent mixture: diethyl ether/ petroleum ether, 5:5) to obtain amine 6 as purple oil 
(242 mg, 1.845 mmol). 
Yield: 69%; 1H NMR (300 MHz, CDCl3) δ 2.057 (s, 2H), 2.49 (d, J = 3 Hz, 1H), 4.79 (d, J = 3 
Hz, 1H), 7.23-7.58 (m, 5H).  
 
Synthesis of tert-butyl ((2S)-3-(1H-indol-3-yl)-1-oxo-1-((1-phenylprop-2-yn-1-yl)amino)propan-
2-yl)carbamate (7). A solution of N-α-Boc-(L)-tryptophan (235 mg, 0.772 mmol) dissolved 
anhydrous dichloromethane (30 mL) under nitrogen atmosphere was cooled by an ice bath, and 1-
phenylprop-2-yn-1-amine (6) (160 mg, 1.220 mmol) was added. When the mixture reached the 
room temperature, monohydrated HOBt (178 mg, 1.165 mmol) and EDAC (231 mg, 1.206 mmol) 
were added. The mixture was stirred at room temperature for 16 h and then the solvent was 
evaporated under reduced pressure. The crude was purified by flash chromatography (eluent 
mixture: ethyl acetate/petroleum ether 3:7) to afford a yellow oil 7 (305 mg, 0.731 mmol) as 
diastereoisomeric mixture. 
 
Yield: 95%; 1H NMR (300 MHz, CDCl3) δ 1.41 (s, 9H), 1.72 (br s, 1H), 2.40 (s, 1H), 3.14-3.23 
(m, 1H), 3.27-3.37 (m, 1H), 4.45 (br s, 1H), 6.29 (dd, J = 9, 24 Hz, 1H), 7.11-7.37 (m, 10H), 7.67 
(d, J = 9 Hz, 1H), 7.99 (d, J = 24 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 28.01 (CH2, THR β), 
28.20 (3CH3), 44.40 and 44.44 (diast. CH, Bn), 54.22 (CH, THR α), 73.04 (≡CH), 81.26 (≡C- or  
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C-O), 81.29 (C-O or ≡C-), 110.10 (C, THR h), 111.21 (CH, THR b), 118.70 and 118.76 (diast. 
CH, THR e), 119.75 (CH, THR d), 122.18 (CH, THR c); 123.34 and 123.41 (diast. CH, THR a), 
126.86 and 126.89 (diast. 2CH, Bn a, e), 127.29 (C, THR g), 128.08 (CH, Bn c), 128.56 and 128.59 
(diast. 2CH, Bn b, d), 136.15 and 136.21 (diast. C, Bn f), 137.71 (C, THR f or C=O Boc), 137.79 
(THR f or C=O Boc), 170.77 (C=O). Chemical Formula: C25H27N3O3. Molar mass: 417.51 g/mol; 
MS (ESI) m/z 440.2  [M+Na] +. 
 
Procedure for the synthesis of 2-(pyridazin-3-yl) ethanol (9). To 3-methylpyridazine (500 mg, 
5.313 mmol) in a microwave vessel under nitrogen atmosphere, 37% formaldehyde (730 mg, 7.975 
mmol), water (1 mL) and piperidine (0.20 mL) were added. The reaction mixture was heated at 
165°C for 30 min in a microwave synthesizer (300 Watts). The solvent was then evaporated under 
reduced pressure and the crude was purified by flash chromatography (eluent mixture: 
dichloromethane/methanol, 9:1) to give the alcohol 9 (259 mg, 2.086 mmol) as a yellow oil.   
Yield: 40%; 1H NMR (300 MHz, CDCl3) δ 2.99 (br s, 1H), 3.19 (t, J = 6 Hz, 2H), 4.11 (t, J = 6 
Hz, 2H), 7.37-7.46 (m, 2H), 9.03-9.07 (m, 1H).  
 
General procedure for the syntheses of 2-(pyridin-2-yl)ethyl methanesulfonate (10) and 2-
(pyridazin-3-yl)ethyl methanesulfonate (11). To the opportune alcohol (2 mmol) in dichloromethane 
(5 mL), DIPEA (4 mmol) was added and the solution was cooled at 0°C. Subsequently 
methanesulfonyl chloride (2.2 mmol) was added and the mixture was stirred at room temperature 
for 3 h. Afterwards water (5 mL) was added and the organic layer was separated,  washed with a 
solution of NaHCO3 (5 mL), dried and concentrated under vacuum.  
The obtained yellow oils were used in the next step without further purification. 
Intermediate 10. Yield: quantitative; 1H NMR (300 MHz, CDCl3) δ 2.95 (s, 3H), 3.42 (t, J = 6 
Hz, 2H), 4.75 (t, J = 6 Hz, 2H), 7.39-7.48 (m, 2H), 9.08-9.14 (m, 1H);  
Intermediate 11. Yield: 79%; 1H NMR (300 MHz, CDCl3) δ 2.87 (s, 3H), 3.20 (t, J = 6.3 Hz, 
2H), 4.64 (t, J = 6.3 Hz, 2H), 7.12-7.23 (m, 2H), 7.58-7.66 (m, 1H) 9.08-9.14 (m, 1H).  
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General procedure for the syntheses of 2-(2-azidoethyl)pyridine (12)  and 3-(2-
azidoethyl)pyridazine  (13). To a solution of the suitable mesylate (1.3 mmol) in DMF (3 mL) under 
stirring, NaN3 (4 mmol) was added and the mixture was heated at 70°C for 3 h, then the solvent was 
evaporated under reduced pressure.  The crudes were purified by flash chromatography (eluent 
mixture: dichloromethane/methanol 95:5) to give the azides as yellow oils. 
Intermediate 12. Yield: 63% (from intermediate 10); 1H NMR (300 MHz, CDCl3) δ 3.23 (t, J = 
6.6 Hz, 2H), 3.83 (t, J = 6.6 Hz, 2H), 7.39-7.48 (m, 2H), 9.08-9.14 (m, 1H);  
Intermediate 13. Yield: 57% (from intermediate 11); 1H NMR (300 MHz, CDCl3) δ 3.06 (t, J = 
6.9 Hz, 2H), 3.71 (t, J = 6.9 Hz, 2H), 7.13-7.22 (m, 2H), 7.58-7.66 (m, 1H), 9.52-9.58 (m, 1H);  
 
General procedure for the syntheses of tert-butyl ((2S)-3-(1H-indol-3-yl)-1-oxo-1-((phenyl(1-(2-
(pyridin-2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)propan-2-yl)carbamate (14) and  tert-butyl 
((2S)-3-(1H-indol-3-yl)-1-oxo-1-((phenyl(1-(2-(pyridazin-3-yl)ethyl)-1H-1,2,3-triazol-4-
yl)methyl)amino)propan-2-yl)carbamate (15). To the solution of the alkyne 7 (0.5 mmol) and the 
opportune azide (0.5 mmol) dissolved in tert-butanol (120 mL), CuSO4 (0.8 mmol), sodium (L)-
ascorbate (2 mmol) and water (60 mL) were respectively added. After stirring at room temperature 
for 18 h, the mixture was extracted with dichloromethane (3 × 40 mL) and washed with brine (1 × 
20 mL). The organic layer was dried and concentrated to reduced pressure. The crudes were 
purified by flash chromatography (eluent mixture: dichloromethane/methanol 95:5) obtaining the 
required triazoles as yellow oils. 
Intermediate 14. Yield: 61%; 1H NMR (300 MHz, CD3OD) δ 1.09-1.25 (m, 1H), 1.38 (s, 9H), 
3.01-3.12 (m, 1H),  3.14-3.23 (m, 1H), 3.28-3.32 (m, 2H), 3.51 (t, J = 6.6 Hz, 2H), 4.40 (t, J = 7.2 
Hz, 1H), 6.13 (d, J = 7.2 Hz, 1H), 6.82-7.63 (m, 15H), 9.00 (s, 1H).  
Intermediate 15. Yield: 92%; 1H NMR (300 MHz, CDCl3) δ 1.39-1.45 (m, 10H), 3.11-3.22 (m, 
1H), 3.27-3.40 (m, 3H), 4.53 (br s, 1H), 4.64-4.74 (m, 2H), 6.09-6.21 (m, 1H), 6.56-7.36 (m, 14H), 
7.53-7.70 (m, 2H), 8.51-8.59 (m, 1H).  
 
General procedure for the syntheses of  (2S)-2-amino-3-(1H-indol-3-yl)-N-(phenyl(1-(2-(pyridin-
2-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)propanamides (1,2) and  (2S)-2-amino-3-(1H-indol-3-yl)-
N-(phenyl(1-(2-(pyridazin-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)propanamides  (3,4). To the 
solution of the opportune Boc-derivative (0.3 mmol) in dichloromethane (3 mL) trifluoroacetic acid 
(3 mL) was slowly added dropwise under stirring, at room temperature. After 3 h, the solution was 
treated with aqueous NaHCO3 until pH 8.5 and the organic layer was dried and concentrated under 
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vacuum. The crudes were purified by flash chromatography (eluent mixture: 
dichloromethane/methanol 9:1) affording the expected products. 
 
Product 1. Chemical Formula: C26H26N8O. Molar mass:  466.55 g/mol. Yield: 44%; light yellow 
solid; M.p. 230°C dec.; MS (ESI) m/z 489.4 [M+Na] +. [α]D 25 = +16.2 (c = 0.4 M, CH3OH). 1H and 
13C NMR spectra data are reported in Table S1 in Electronic supplementary materials 2 
 
Product 2. Chemical Formula: C26H26N8O. Molar mass: 466.55 g/mol. Yield: 39%; light yellow 
solid; M.p. 182.4°C; MS (ESI) m/z 489.4 [M+Na] +.  [α]D 25 = +9.3 (c = 0.4 M, CH3OH). 1H and 13C 
NMR spectra data are reported in Table S1 in Electronic supplementary materials 2. 
 
Product 3. Chemical Formula: C27H27N7O. Molar mass: 465.56 g/mol. Yield: 32%; light pink 
foam; MS (ESI) m/z 466.2 [M+1] +. [α]D 25 = +7.4 (c = 0.8 M, CH3OH).1H and 13C NMR spectra 
data are reported in Table S1 in Electronic supplementary materials 2. 
 
Product 4.Chemical Formula: C27H27N7O. Molar mass: 465.56 g/mol. Yield: 50%; light yellow 
foam; MS (ESI) m/z 466.2 [M+1] +.
 [α]D 25 = +13.02 (c = 0.8 M, CH3OH). 1H and 13C NMR spectra 
data are reported in Table S1in Electronic supplementary materials 2. 
 
NMR Spectroscopy. NMR spectra of compounds 1-4 and 7 were recorded with a Bruker 
AVANCE-500 spectrometer operating at 500.13 MHz for 1H or at 125.76 MHz for 13C NMR 
spectra using a 5 mm z-PFG (pulsed field gradient) broadband reverse probe. Chemical shifts are 
reported on the  (ppm) scale and are relative to residual CH3OD at 3.30 ppm (central line) for 1H 
NMR spectra, and relative to CD3OD at 47.0 ppm (central line) for 
13C NMR spectra. The data were 
collected and processed by XWIN-NMR software (Bruker) running on a PC with Microsoft 
Windows xp. Compounds (about 15 mg) were dissolved in CD3OD (0.75 mL). The solutions were 
put in a 5 mm NMR tube and the spectra recorded at 296 K. The signal assignment was given by a 
combination of 1D and 2D (COSY, NOESY and HSQC) experiments, using standard Bruker pulse 
programs. The 1H-1H and 13C-1H bond correlations were confirmed by COSY and HSQC 
experiment using Z-PFGs. The pulse widths were 7.50 µs (90°) for 1H and 14.75 µs (90°) for 13C. 
Typically 32 K data points were collected for one-dimensional spectra. Spectral width was 14.0 
ppm (7002 Hz) for 1H NMR (digital resolution: 0.21 Hz per point). 
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2D experiments parameters were as follows. For 1H-1H correlations: relaxation delay 2.0 s, data 
matrix 1 K  1 K (512 experiments to 1 K zero filling in F1, 1 K in F2), 2 or 32 transients in each 
experiment for COSY and NOESY respectively, spectral width 9.00 ppm (4496.4 Hz). The NOESY 
spectra were generated with a mixing time of 1.0 s and acquired in the TPPI mode. There were not 
significant differences in the results obtained at different mixing times (2.0 – 3.0 s). For 13C-1H 
correlations (HSQC): relaxation delay 2.5 s, data matrix 1K  1K (512 experiments to 1 K zero 
filling in F1, 1K in F2), 6 transients in each experiment, spectral width 7.0 ppm (3501 Hz) in the 
proton domain and 180.0 ppm (22638 Hz) in the carbon domain. A sinebell weighting was applied 
to each dimension. All 2D spectra were processed with the Bruker software package. 
 
Conformational analysis. All the calculations were carried out using the GAUSSIAN09 
program package [43]. Optimizations were performed at the B3LYP/6-31G(d) level [30,31], 
considering all degrees of conformational freedom and on the basis of experimental NOESY 
correlations. Vibrational frequencies were computed at the same level of theory to verify that the 
optimized structures were minima. The population percentages were calculated through the 
Boltzmann equation. GIAO NMR calculations were carried out at the B3LYP/6-31G(d) level 
[30,31]. 
 
Surface Plasmon Resonance Assays. SPR runs were conducted on a Biacore T100 instrument 
(GE Healthcare) at 25°C with a flow rate of 50 μL/min, unless otherwise specified. Running buffer 
(RB) consisted of 1x PBS (1 mM KH2PO4, 5.6 mM Na2HPO4, 154.5 mM NaCl, pH 7.4), 0.01% v/v 
P20, and varying amounts of DMSO (Quality Biologicals). Binding and equilibrium constants were 
determined with Scrubber (BioLogic™). A double-referencing method was applied to correct for 
nonspecific binding to the chip with interspersed blank injections correcting for baseline drifts. 
Changes in refractive index due to DMSO were accounted for with a DMSO calibration curve. 
Furthermore, a positive control experiment using a defined amount of the binding partner of Atg8 in 
the presence of DMSO was interspersed every 4th injection. Using this positive control allows 
monitoring the decay of the ligand attached to the SPR chip. No decay was observed throughout the 
experiments, 
 
P. falciparum Blood Stage Culturing. Cultures of P. falciparum 3D7 strain were maintained 
using modified, previously published methods at 37°C, 2% hematocrit of human red blood cells 
[44]. Complete culture media consisted of sterile RPMI 1640 media (Life Technologies) 
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supplemented with 10% human serum and 0.005% hypoxanthine and buffered with final 
concentrations of 0.6% HEPES and 0.26% NaHCO3. The P. falciparum 3D7 strain was maintained 
at 5% CO2, 5% O2, and 90% N2 atmosphere.  
 
SYBR Green I Growth Inhibition Assay. Ten microliters of 10x compound diluted in RPMI 
1640 media (Gibco) with a constant concentration of 1% DMSO were added to a 96 well plate 
(Costar), 90 μL of 1.5% ring stage, synchronized with 5% w/v sorbitol P. falciparum 3D7 parasites, 
1% hematocrit, in culture media with 10% v/v human serum with 10 μg/mL gentamycin. Each 
compound concentration and 1% v/v DMSO controls were run in triplicate. Plates were incubated at 
37°C in 5% O2, 5% CO2, and 90% N2 for 72 h. Plates were frozen, thawed, and incubated with 100 
μL 2× SYBR green in lysis buffer (20 mM Tris pH 7.5, 5 mM EDTA, 0.008% Saponin, 0.08% 
TritonX-100) in the dark for at least 1 h. Fluorescence was measured with a plate reader 
(SpectraMax I3X, Molecular Dimensions) at excitation/emission wavelengths of 485/ 535 
nm. Analysis was carried out using GraphPad Prism and treating the DMSO vehicle control as 
100% growth and the 100 µM Chloroquine control as 0% growth. Automatic outlier control was 
employed using log (inhibitor) versus the normalized response. 
 
MTT assay. The HepG2 cell line was bought from ATCC (HB-8065, ATCC from LGC Standards, 
Milan, Italy) and was cultured in DMEM high glucose with stable L-glutamine, supplemented with 
10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin (complete growth medium) with 
incubation at 37 °C under 5% CO2 atmosphere. HepG2 cells were used for no more than 20 
passages after thawing, because the increase in number of passages may change the cell 
characteristics and impair assay results. A total of 3 x 104 HepG2 cells/well were seeded in 96-well 
plates and treated with 100.0 40.0 and 1.0 µM of compounds 1 and 2, respectively, or vehicle 
(DMSO) in complete growth media for 24 and 48 h. Subsequently, the treatment solvent was 
aspirated and 100 µL/well of MTT filtered solution added for 2 h. After the incubation time, 0.5 
mg/mL MTT solution was aspirated and 100 µL/well of MTT lysis buffer (8 mM HCl + 0.5% NP-
40 in DMSO) added. After 5 min of slow shaking, the absorbance at 570 nm and 630 nm (reference 
wavelength) were read by a microplate reader Synergy H1 from BioTek Germany (Bad 
Friedrichshall, Germany). 
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Electronic supplementary material 
”Supplementary_material1.pdf” contains the atoms distance fluctuation plots acquired by MD 
simulations, and a figure showing the docking results. Conformational analysis, NMR studies and 
spectra can be found in Supplementary_material2.pdf. 
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